Please login to the form below

Not currently logged in
Email:
Password:

lurasidone

This page shows the latest lurasidone news and features for those working in and with pharma, biotech and healthcare.

EU approval for Takeda’s schizophrenia drug

EU approval for Takeda’s schizophrenia drug

Takeda and development partner Dainippon Sumitomo Pharma have won European approval for their schizophrenia treatment Latuda (lurasidone).

Latest news

  • GSK's diabetes drug among CHMP recommendations GSK's diabetes drug among CHMP recommendations

    2013. Takeda's antipsychotic and Linepharma's Hemoprostol. Elsewhere in the CHMP opinions, Takeda received a recommendation for the use of Latuda (lurasidone) in the treatment of adults with schizophrenia.

  • Schizophrenia treatments

    Lurasidone, an antagonist of dopamine D2, serotonin 2A, serotonin 7, serotonin 2C and a partial agonist of serotonin 1A, is being marketed by Sunovion Pharmaceuticals.

  • Coronary conundrums

    US. Lurasidone. Latuda (Sunovion Pharmaceuticals). Schizophrenia. US an Puerto Rico. Paracetamol.

  • DSP buys Sepracor

    The move comes as DSP prepares to launch its schizophrenia drug lurasidone, which last month significantly outperformed placebo in late-stage trials. ... The acquisition gives DSP the sales and marketing infrastructure in the US it needs to commercialise

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics